The p53 tumor suppressor gene continues to be distinguished as the most frequently mutated gene in human cancer. Induction of p53 can cause either growth arrest or apoptosis, but it is believed that p53's apoptotic functions largely underlie its selection for inactivation in cancer. Currently, there are several gaps in our knowledge about the p53-dependent apoptosis pathway. While it is known that p53 can transcriptionally activate a number of genes involved in cell death, it is also a transcriptional repressor, and can repress the expression of anti-apoptotic genes. The contribution of transcriptional repression by p53 to cell death has never been determined, and will be a focus of the current proposal. p53-dependent transcriptional repression occurs through diverse binding sites on the promoters of repressed genes. However, we believe we have found a focal point in transcriptional repression by this protein, the p53-Sin3-HDAC (histone deacetylase) complex. The hypothesis that this complex is used as a common mechanism of repression by p53 will be tested. Finally, we have found that the codon 72 polymorphism in p53 alters its transcriptional properties. Specifically, the arginine (R72) variant of p53 has greatly enhanced ability to transactivate a subset ofp53-induced genes, along with markedly increased ability to induce apoptosis. We will test the hypothesis that transactivation of this subset of pro-apoptotic genes is critical for the cell's decision to undergo growth arrest or apoptosis. At the heart of this application is the proline-rich domain of p53. It has been known for many years that deletion of this domain renders p53 impaired for apoptosis induction, but its function in cell death has never been fully understood. Sin3-binding and the codon 72 polymorphism both occur within this domain. Completion of the proposed studies will shed necessary light on the function of the proline-rich domain of p53 in apoptosis induction.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA080854-06A1
Application #
6821050
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Blair, Donald G
Project Start
1999-04-01
Project End
2009-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
6
Fiscal Year
2004
Total Cost
$301,590
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Pimkina, Julia; Humbey, Olivier; Zilfou, Jack T et al. (2009) ARF induces autophagy by virtue of interaction with Bcl-xl. J Biol Chem 284:2803-10
Pimkina, Julia; Murphy, Maureen E (2009) ARF, autophagy and tumor suppression. Autophagy 5:397-9
Humbey, Olivier; Pimkina, Julia; Zilfou, Jack T et al. (2008) The ARF tumor suppressor can promote the progression of some tumors. Cancer Res 68:9608-13
Pietsch, E Christine; Murphy, Maureen E (2008) Low risk HPV-E6 traps p53 in the cytoplasm and induces p53-dependent apoptosis. Cancer Biol Ther 7:1916-8
Pietsch, E C; Sykes, S M; McMahon, S B et al. (2008) The p53 family and programmed cell death. Oncogene 27:6507-21
Murphy, Maureen E; Leu, J I-Ju; George, Donna L (2004) p53 moves to mitochondria: a turn on the path to apoptosis. Cell Cycle 3:836-9
Leu, J I-Ju; Dumont, Patrick; Hafey, Michael et al. (2004) Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6:443-50
Hoffman, William H; Biade, Siham; Zilfou, Jack T et al. (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247-57
Zilfou, J T; Hoffman, W H; Sank, M et al. (2001) The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol Cell Biol 21:3974-85
Murphy, M; Ahn, J; Walker, K K et al. (1999) Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13:2490-501